Introduction: Dermatological reactions are relatively common in people with CF (PwCF) treated with elexacaftor/tezacaftor/ivacaftor (ETI). Clinical trial data suggests rates as high as 10.9% following initiation of therapy ( 1 Middleton PG et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381: 1809-1819 Crossref PubMed Scopus (868) Google Scholar ). In the UK, 290 skin and subcutaneous spontaneous suspected adverse drug reactions have been reported through the Yellow Card Scheme (https://info.mhra.gov.uk/).